Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q1 2026 results for quarter ended March 31, 2026, released May 6, 2026.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, released May 6, 2026
- Press release covers corporate developments and financial results
- Conference call and webcast referenced for management commentary
- Investor-relevant figures and outlook contained in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Item 7.01 provides Regulation FD disclosure through Exhibit 99.1
- Exhibit 99.1 is furnished, not filed, limiting Section 18 Exchange Act liability
- Exhibit content requires review for the event’s substantive investor implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.